ImmunocorePlc-adr Share Price (NASDAQ: IMCR)

$32.45

▲

0.11

(0.34%)

Last updated on August 21, 2025 at 1:29 AM IST

$₹

Check the interactive ImmunocorePlc-adr Stock chart to analyse performance

ImmunocorePlc-adr stock performance

as on August 21, 2025 at 1:29 AM IST

Today's Low:$32.30
Today's High:$32.94
$32.45
0.46%
Downside
Day's Volatility :1.94%
Upside
1.49%
52 Weeks Low:$23.15
52 Weeks High:$39.33
$32.45
28.66%
Downside
52 Weeks Volatility :41.14%
Upside
17.49%

ImmunocorePlc-adr Stock Returns

Period	Immunocore Holdings Plc-adr	Sector (Health Care)	Index (Russel 2000)
3 Months	3.78%	1.5%	0.0%
6 Months	8.44%	-7.1%	0.0%
1 Year	-11.37%	-11.4%	0.0%
3 Years	-36.86%	2.9%	-9.6%

Immunocore Holdings Plc-adr Key Stats

Check ImmunocorePlc-adr key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$32.34
Open	$32.525
Today's High	$32.94
Today's Low	$32.3
Market Capitalization	$1.6B
Today's Volume	$216.0K
52 Week High	$39.3295
52 Week Low	$23.15
Revenue TTM	$356.1M
EBITDA	$-24.6M
Earnings Per Share (EPS)	$-0.41
Profit Margin	-5.7%
Quarterly Earnings Growth YOY	8.22%
Return On Equity TTM	-5.43%

Stock Returns calculator for ImmunocorePlc-adr Stock including INR - Dollar returns

The ImmunocorePlc-adr stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

ImmunocorePlc-adr investment value today

Current value as on today

₹91,355

Returns

₹8,645

(-8.64%)

Returns from ImmunocorePlc-adr Stock

₹12,534 (-12.53%)

Dollar Returns*

₹3,889 (+3.89%)

Indian investors sentiment towards ImmunocorePlc-adr Stock

-38%

Period: Jul 21, 2025 to Aug 20, 2025. Change in 30 Days versus previous period

Search interest for ImmunocorePlc-adr Stock from India on INDmoney has decreased by -38% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Immunocore Holdings Plc-adr

Name
Holdings %
Name
Holdings %
T. Rowe Price Investment Management,Inc.
14.07%
RTW INVESTMENTS, LLC
9.69%
FMR Inc
9.64%
Wellington Management Company LLP
8.39%
PRIMECAP Management Company
7.51%
Bellevue Group AG
4.86%

Analyst Recommendation on ImmunocorePlc-adr Stock

Rating

Trend

Buy

91%Buy

8%Hold

0%Sell

Based on 24 Wall street analysts offering stock ratings for ImmunocorePlc-adr(by analysts ranked 0 to 5 stars)

ImmunocorePlc-adr Share Price Target

What analysts predicted

Upside of 91.05%

Target:

$62.00

Current:

$32.45

ImmunocorePlc-adr share price target is $62.00, a slight Upside of 91.05% compared to current price of $32.45 as per analysts' prediction.

ImmunocorePlc-adr Stock Insights

Price Movement
In the last 1 month, IMCR stock has moved down by -10.8%
Increasing Revenue
Revenue is up for the last 6 quarters, 70.50M → 97.96M (in $), with an average increase of 6.3% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 5.02M → -10.3M (in $), with an average decrease of 305.1% per quarter
IMCR vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 63.3% return, outperforming this stock by 76.0%
IMCR vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.3% return, outperforming this stock by 150.0%
Price to Sales
ForIMCR every $1 of sales, investors are willing to pay $4.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $24.1 for every $1 of sales.

Immunocore Holdings Plc-adr Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$33.6M	↑ 8.52%
Net Income	$-136.1M	↑ 45.09%
Net Profit Margin	-404.89%	↓ 102.07%

	FY20	Y/Y Change
Revenue	$40.5M	↑ 17.32%
Net Income	$-99.5M	↓ 28.71%
Net Profit Margin	-246.04%	↑ 158.85%

	FY21	Y/Y Change
Revenue	$35.3M	↓ 11.93%
Net Income	$-175.0M	↑ 77.51%
Net Profit Margin	-495.94%	↓ 249.9%

	FY22	Y/Y Change
Revenue	$175.0M	↑ 441.99%
Net Income	$-50.2M	↓ 68.66%
Net Profit Margin	-28.68%	↑ 467.26%

	FY23	Y/Y Change
Revenue	$315.8M	↑ 73.53%
Net Income	$-70.0M	↑ 34.11%
Net Profit Margin	-22.17%	↑ 6.51%

	FY24	Y/Y Change
Revenue	$310.2M	↑ 24.37%
Net Income	$-51.1M	↓ 7.6%
Net Profit Margin	-16.47%	↑ 5.7%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$89.6M	↓ 33.26%
Net Income	$-31.1M	↓ 7.5%
Net Profit Margin	-34.66%	↓ 9.65%

	Q2 FY24	Q/Q Change
Revenue	$75.4M	↑ 6.95%
Net Income	$-11.6M	↓ 52.46%
Net Profit Margin	-15.41%	↑ 19.25%

	Q3 FY24	Q/Q Change
Revenue	$80.2M	↑ 6.43%
Net Income	$8.7M	↓ 175.21%
Net Profit Margin	10.89%	↑ 26.3%

	Q4 FY24	Q/Q Change
Revenue	$84.1M	↑ 4.74%
Net Income	$-23.8M	↓ 372.1%
Net Profit Margin	-28.28%	↓ 39.17%

	Q1 FY25	Q/Q Change
Revenue	$93.9M	↑ 11.69%
Net Income	$5.0M	↓ 121.13%
Net Profit Margin	5.35%	↑ 33.63%

	Q2 FY25	Q/Q Change
Revenue	$98.0M	↑ 4.35%
Net Income	$-10.3M	↓ 305.06%
Net Profit Margin	-10.51%	↓ 15.86%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-97.3M	↓ 414.2%

	FY20	Y/Y Change
Profit	$-60.0M	↓ 39.86%

	FY21	Y/Y Change
Profit	$-62.1M	↑ 4.5%

	FY22	Y/Y Change
Profit	$174.4M	↓ 406.78%

	FY23	Y/Y Change
Profit	$314.5M	↑ 73.36%

	FY24	Y/Y Change
Profit	$307.5M	↑ 23.79%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$89.3M	↓ 33.65%

	Q2 FY24	Q/Q Change
Profit	$73.7M	↑ 4.89%

	Q3 FY24	Q/Q Change
Profit	$79.8M	↑ 8.29%

	Q4 FY24	Q/Q Change
Profit	$83.7M	↑ 4.91%

	Q1 FY25	Q/Q Change
Profit	$93.1M	↑ 11.14%

	Q2 FY25	Q/Q Change
Profit	$96.9M	↑ 4.16%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-132.7M	↑ 509.74%
Investing Cash Flow	$-5.4M	↓ 107.13%
Financing Cash Flow	$72.2M	↑ 54481.19%

	FY20	Y/Y Change
Operating Cash Flow	$-81.4M	↓ 40.25%
Investing Cash Flow	$627.3K	↓ 111.29%
Financing Cash Flow	$155.7M	↑ 110.32%

	FY21	Y/Y Change
Operating Cash Flow	$-172.6M	↑ 114.2%
Investing Cash Flow	$-658.5K	↓ 206.0%
Financing Cash Flow	$367.5M	↑ 138.27%

	FY22	Y/Y Change
Operating Cash Flow	$-38.1M	↓ 75.9%
Investing Cash Flow	$283.6K	↓ 147.07%
Financing Cash Flow	$168.3M	↓ 49.96%

	FY23	Y/Y Change
Operating Cash Flow	$3.7M	↓ 109.4%
Investing Cash Flow	$-6.9M	↓ 2428.33%
Financing Cash Flow	$43.5M	↓ 75.15%

	FY24	Y/Y Change
Operating Cash Flow	$26.1M	↑ 786.43%
Investing Cash Flow	$-355.1M	↑ 6446.16%
Financing Cash Flow	$343.9M	↑ 901.23%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-5.8M	↓ 57.7%
Investing Cash Flow	$-546.5K	↓ 96.56%
Financing Cash Flow	$503.3M	↑ 1632.47%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$23.5M	↓ 611.71%
Investing Cash Flow	$-350.3M	↑ 81372.33%
Financing Cash Flow	$-818.0K	↓ 100.21%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$21.1M	↓ 9.99%
Investing Cash Flow	$-828.0K	↓ 99.76%
Financing Cash Flow	$198.0K	↓ 124.21%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-14.0M	↓ 166.03%
Investing Cash Flow	$-3.5M	↑ 327.54%
Financing Cash Flow	$-51.5M	↓ 26115.66%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$435.0K	↓ 103.12%
Investing Cash Flow	$9.7M	↓ 374.07%
Financing Cash Flow	$2.6M	↓ 104.95%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$26.0M	↑ 5868.74%
Investing Cash Flow	$-30.4M	↓ 413.48%
Financing Cash Flow	$3.7M	↑ 43.87%

ImmunocorePlc-adr Technicals Summary

Sell

Neutral

Buy

ImmunocorePlc-adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Immunocore Holdings Plc-adr Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Immunocore Holdings Plc-adr	-12.29%	8.44%	-11.37%	-36.86%	-18.27%
Regeneron Pharmaceuticals, Inc.	4.65%	-17.97%	-51.83%	-6.73%	-4.01%
Beone Medicines Ltd	5.84%	28.11%	58.02%	80.84%	31.78%
Vertex Pharmaceuticals Incorporated	-14.79%	-18.66%	-19.63%	32.96%	46.09%
Alnylam Pharmaceuticals, Inc.	43.03%	82.65%	64.22%	110.39%	247.97%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Immunocore Holdings Plc-adr	NA	NA	NA	-0.67	-0.05	-0.02	NA	7.71
Regeneron Pharmaceuticals, Inc.	14.47	14.47	1.18	39.36	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.73	27.73	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Immunocore Holdings Plc-adr	Buy	$1.6B	-18.27%	NA	-5.7%
Regeneron Pharmaceuticals, Inc.	Buy	$60.8B	-4.01%	14.47	31.37%
Beone Medicines Ltd	NA	$39.3B	31.78%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.0B	46.09%	27.73	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.8B	247.97%	NA	-12.96%

About Immunocore Holdings Plc-adr

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Organization	ImmunocorePlc-adr
Employees	493
CEO	Dr. Bahija Jallal Ph.D.
Industry	Services

Key Management of Immunocore Holdings Plc-adr

Name	Title
Dr. Bahija Jallal Ph.D.	CEO & Executive Director
Mr. Travis A. Coy	CFO, Executive VP & Head of Corporate Development
Ms. Tina St. Leger	Executive VP & Chief Human Resources Officer
Dr. David Berman M.D., Ph.D.	Executive Vice President of Research & Development
Mr. John Trainer M.B.A.	SVP & Chief Operating Officer
Mr. John Goll III	SVP, Finance & Chief Accounting Officer
Ms. Annelise Vuidepot Ph.D.	Senior VP, CTO and Research & UK Site Lead
Mr. Sean D. Buckley	VP & Chief Information Officer
Mr. Clayton Robertson	Head of Investor Relations
Ms. Lily Margaret Hepworth	Executive VP, General Counsel & Company Secretary

Important FAQs about investing in IMCR Stock from India :

What is ImmunocorePlc-adr share price today?

ImmunocorePlc-adr share price today is $32.45 as on August 21, 2025 at 1:29 AM IST at the close of the market. ImmunocorePlc-adr share today touched a day high of $32.94 and a low of $32.30.

What is the 52 week high and 52 week low for ImmunocorePlc-adr share?

ImmunocorePlc-adr share touched a 52 week high of $39.33 and a 52 week low of $23.15. ImmunocorePlc-adr stock price today i.e. August 21, 2025 at 1:29 AM IST is closed at $32.45, lower by 17.49% versus the 52 week high.

How to invest in ImmunocorePlc-adr Stock (IMCR) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for ImmunocorePlc-adr on INDmoney app. Click on Buy button. You can invest as low as $1.5 in ImmunocorePlc-adr Shares that will get you 0.0462 shares as per ImmunocorePlc-adr share price of $32.45 per share as on August 21, 2025 at 1:29 AM IST.

What is the minimum amount required to buy ImmunocorePlc-adr Stock (IMCR) from India?

Indian investors can start investing in ImmunocorePlc-adr (IMCR) shares with as little as ₹87.0225 or $1 (as of August 21, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹870.22 in ImmunocorePlc-adr stock (as per the Rupee-Dollar exchange rate as on August 21, 2025). Based on ImmunocorePlc-adr share’s latest price of $32.45 as on August 21, 2025 at 1:29 AM IST, you will get 0.3082 shares of ImmunocorePlc-adr. Learn more about fractional shares .

What are the returns that ImmunocorePlc-adr has given to Indian investors in the last 5 years?

ImmunocorePlc-adr stock has given -18.27% share price returns and 16.26% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?